Session » (0673–0690) Vasculitis – ANCA-Associated Poster I: Treatment Outcomes
-
Abstract Number: 0673
Reporting of Race, Ethnicity, Sex, Gender, Socioeconomic Status and Representativeness of Race and Ethnicity in ANCA-associated Vasculitis Randomized Trials
-
Abstract Number: 0674
Efficacy and Safety of Mepolizumab During Maintenance Therapy in Patients with Eosinophilic Granulomatosis with Polyangiitis
-
Abstract Number: 0675
Investigating the Impact of anti-IL5 Therapy in the Management of Relapsing and Refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA); A Three Year Longitudinal Perspective and Beyond
-
Abstract Number: 0676
Mepolizumab Can Achieve Glucocorticoid Discontinuation in Eosinophilic Granulomatosis with Polyangiitis Patients Regardless of IgE Levels: A Retrospective Study at a Single Center
-
Abstract Number: 0678
Benralizumab in Eosinophilic Granulomatosis with Polyangiitis
-
Abstract Number: 0679
Long-term Safety of Rituximab (Mabthera) in Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA): Rituximab Surveillance Study in VASculitis (RIVAS)
-
Abstract Number: 0680
Risk Factors for Hypogammaglobulinemia and Association with Relapse and Severe Infections in ANCA-Associated Vasculitis: A Retrospective Single-Centre Cohort Study
-
Abstract Number: 0681
Real-World Outcomes for Remission Induction in Working-Age Adults with Severe Anti-Neutrophil Cytoplasmic Antibody-associated Vasculitis
-
Abstract Number: 0682
Avacopan in ANCA-associated Vasculitis Received Intensified Induction Therapy with Cyclophosphamide Plus Rituximab – Retrospective Case Serial of 12 Patients
-
Abstract Number: 0684
Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
-
Abstract Number: 0685
Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in a Phase 3 Trial
-
Abstract Number: 0686
Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis
-
Abstract Number: 0687
Avacopan for the Treatment of ANCA-associated Vasculitis. Real World Experience in Spain
-
Abstract Number: 0688
Efficacy and Safety Experience with Avacopan Beyond 52 Weeks in the Early Access Program (EAP)